GermFlare Announces Its Professional Handheld UVC Light Kills 99.99% of MRSA and P. Aeruginosa in Laboratory Testing

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

March 2, 2021

GermFlare, based in Denmark, today proudly reported its handheld UVC light called “GermFlare” to achieve greater than 99.99%, or 4log, inactivation of both Methicillin-Resistant Staphylococcus Aureus (MRSA) and Pseudomonas Aeruginosa (PA) in less than 5 seconds at a distance of 3.9 inches (10 cm).

Testing on the two bacteria strains was conducted by ALS Denmark A/S (part of ALS Laboratories), an accredited global certified laboratory.

GermFlare, UVC

The testing parameters were carefully selected to simulated how the effect of the GermFlare would be in the hands of its core user, the healthcare personnel at hospitals. GermFlare has previously been proven to inactivate SARS-CoV-2 at the Department of Immunology and Microbiology and Department of Infectious Diseases, Hvidovre Hospital, Denmark.

“Our focus is to provide a solution to the global Hospital Acquired Infection (HAI) problem and as MRSA is one of those bacteria our core users fight against every day, we are very pleased with the results.”

“We hope this test and the results can provide some comfort and confidence to the Healthcare personnel working in areas where there is an increased risk of contracting HAIs.”

“When the user starts to incorporate the use of GermFlare more in their daily routines the risk of being infected by any harmful pathogen decreases noticeable, and it could just be a quick 5-second treatment of any hotspots they touch. Even if the nurse forgets to use rubbing alcohol after they touched a door handle, they do not need to worry because if they used the GermFlare it would have killed the harmful pathogens and broken the chain of infection.” – states Flemming Dahlin, Chief Executive Officer, GermFlare.

 

spot_img

DON'T MISS

Related Articles